Activity of amoxicillin/clavulanate in patients with tuberculosis

Clinical Infectious Diseases

Volumn 26, Issue 4, 1998, Pages 874-879

  Chambers, Henry F ^a   Kocagöz, Tanil ^b   Sipit, Tugrul ^b   Turner, Joan ^b   Hopewell, Philip C ^b  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b NONE

Author keywords

[No Author keywords available]

Indexed keywords

AMOXICILLIN PLUS CLAVULANIC ACID; BETA LACTAM ANTIBIOTIC; ISONIAZID; OFLOXACIN; RIFAMPICIN; SULTAMICILLIN;

ANTIBIOTIC SENSITIVITY; ARTICLE; BACTERICIDAL ACTIVITY; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; HUMAN; LUNG TUBERCULOSIS; MINIMUM INHIBITORY CONCENTRATION; MULTICENTER STUDY; MYCOBACTERIUM TUBERCULOSIS; ORAL DRUG ADMINISTRATION; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; SPUTUM CULTURE;

EID: 0031916549     PISSN: 10584838     EISSN: None     Source Type: Journal    
DOI: 10.1086/513945     Document Type: Article

References (23)

1. Goble M, Iseman MD, Madsen LA, et al. Treatment of 171 patients with pulmonary tuberculosis resistant to isoniazid and rifampin. N Engl J Med 1993;328:527-32.
2. Brennan PJ, Nikaido H. The envelope of mycobacteria. Annu Rev Biochem 1995;64:29-63.
3. Finch R. β-Lactam antibiotics and mycobacteria. J Antimicrob Chemother 1986;18:6-8.
4. Bush K. Characterization of β-lactamases: groups 1, 2a, 2b, and 2b′. Antimicrob Agents Chemother 1989;33:264-70.
5. Kasik J. Mycobacterial β3-lactamases. In: Hamilton-Miller J, Smith J, eds. β-Lactamases. London: Academic Press, 1979:339-50.
6. Kasik J. The nature of mycobacterial penicillinase. Am Rev Respir Dis 1965;91:117-9.
7. v strain of Mycobacterium tuberculosis. Am Rev Respir Dis 1967;95:12-9.
8. Kasik J, Weber M, Winberg E, et al. The synergistic effect of dicloxacillin and penicillin G on murine tuberculosis. Am Rev Respir Dis 1966;94:260-1.
9. Casal M, Rodriguez F, Benavente M, et al. In vitro susceptibility of Mycobacterium tuberculosis, Mycobacterium fortuitum and Mycobacterium chelonei to Augmentin. Eur J Clin Microbiol 1986;5:453-4.
10. Cynamon MH, Palmer GS. In vitro activity of amoxicillin in combination with clavulanic acid against Mycobacterium tuberculosis. Antimicrob Agents Chemother 1983;24:429-31.
11. Watt B, Edwards JR, Rayner A, et al. In vitro activity of meropenem and imipenem against mycobacteria: development of a daily antibiotic dosing schedule. Tubercle Lung Dis 1992;73:134-6.
12. Chambers HF, Moreau D, Yajko D, et al. Can penicillins and other β-lactam antibiotics be used to treat tuberculosis? Antimicrob Agents Chemother 1995;39:2620-4.
13. Nadler JP, Berger J, Nord JA, et al. Amoxicillin-clavulanic acid for treating drug-resistant Mycobacterium tuberculosis. Chest 1991;99:1025-6.
14. Yew WW, Wong CF, Lee J, et al. Do β-lactam-β-lactamase inhibitor combinations have a place in the treatment of multidrug resistant tuberculosis? Tubercle Lung Dis 1995;76:90-1.
15. Kent PT, Kubica GP. Public health mycobacteriology: a guide to the level III laboratory. Atlanta U.S. Department of Health and Human Services, Public Health Service, Centers for Disease Control, 1985.
16. Jindani A, Aber VR, Edwards EA, et al. The early bactericidal activity of drugs in patients with pulmonary tuberculosis. Am Rev Respir Dis 1980;121:939-49.
17. Yajko DM, Wagner C, Tevere V, et al. Quantitative culture of Mycobacterium tuberculosis from clinical sputum specimens and the dilution end-point of its detection using Amplicor PCR assay. J Clin Microbiol 1995;33:1944-7.
18. Heifits LB. Antituberculous drugs: antimicrobial activity in vitro. In: Heifits LB, ed. Drug susceptibility in the chemotherapy of mycobacterial infections. Boca Raton, Florida: CRC Press, 1991:13-57.
19. Inderlied C. Antimycobacterial agents: in vitro susceptibility testing, spectrums of activity, mechanisms of action and resistance, and assays for activity in biological fluids. In: Lorian V, ed. Antibiotics in laboratory medicine. 3rd ed. Philadelphia: Williams & Wilkins, 1991:134-97.
20. Siddiqui S. BACTEC TB system products and procedure manual. Section IV: drug susceptibility testing. Towson, Maryland: Becton Dickinson, 1989.
21. Kennedy N, Fox R, Kisyombe M, et al. Early bactericidal and sterilizing activities of ciprofloxacin in pulmonary tuberculosis. Am Rev Respir Dis 1993;148:1547-51.
22. Mitchison DA. Assessment of new sterilizing drugs for treating pulmonary tuberculosis by culture at 2 months. Am Rev Respir Dis 1993;147:1062-3.
23. Sirgel FA, Botha FJ, Parkin DP, et al. The early bactericidal activity of rifabutin in patients with pulmonary tuberculosis, measured by sputum viable counts: a new method of drug assessment. J Antimicrob Chemother 1993;32:867-75.